2. Academic Validation
  3. Cardiomyocyte mechanical contraction sensitivity-enhanced biosensing for precise drug evaluation

Cardiomyocyte mechanical contraction sensitivity-enhanced biosensing for precise drug evaluation

  • Biosens Bioelectron. 2026 Apr 15:298:118405. doi: 10.1016/j.bios.2026.118405.
Tao Liang 1,  Zhekun Jia 1,  Chengyun Wang 1,  Jiaru Fang 2,  Dongxin Xu 3,  Hao Wang 4,  Ling Zou 5,  Zhen Wang 6,  Ning Hu 7
Affiliations

Affiliations

  • 1 Laboratory Medicine Center, Department of Transfusion Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China; Department of Chemistry, Zhejiang-Israel Joint Laboratory of Self-Assembling Functional Materials, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • 2 Department of Neurology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
  • 3 Department of General Surgery, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents Health and Diseases, Hangzhou, 310052, China.
  • 4 Key Laboratory for Biomedical Engineering of Ministry of Education, Department of Biomedical Engineering, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, 310058, China.
  • 5 Department of Chemistry, Zhejiang-Israel Joint Laboratory of Self-Assembling Functional Materials, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • 6 Laboratory Medicine Center, Department of Transfusion Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China. Electronic address: [email protected].
  • 7 Department of Chemistry, Zhejiang-Israel Joint Laboratory of Self-Assembling Functional Materials, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China; Department of General Surgery, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents Health and Diseases, Hangzhou, 310052, China; State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai, 200050, China. Electronic address: [email protected].
PMID: 41558344 DOI: 10.1016/j.bios.2026.118405
Abstract

Cardiovascular diseases is the leading cause of mortality worldwide, underscoring the critical importance of preclinical drug screening and cardiac safety in cardiovascular therapeutics to mitigate the immense health and economic burdens. In vitro cardiomyocyte models have been utilized to develop drug evaluation biosensing platforms, leveraging their rhythmic mechanical contractions. However, conventional label-based methodologies pose challenges for long-term monitoring due to the drug adverse effect and phototoxicity, and video-based strategies necessitate high-resolution imaging but is constrained by low frame rates, while label-free biosensing platforms often require costly and time-consuming microfabrication techniques. Here, we introduce a mechanical contraction biosensing platform that incorporates a multi-channel size-regulable impedance sensor (SRIS) with a custom-developed detection system. The fabrication process of SRIS is straightforward and efficient, providing substantial benefits in terms of economic and temporal costs. Further, the SRIS platform strategically regulates three distinct electrode sizes, and the optimal driving frequency of each sensor is systematically determined. Through long-term dynamic cellular viability and contraction assessment, the cardiomyocyte-based contraction model is refined and prepared for drug evaluation. Three typical cardiac drugs are applied to modulate cardiomyocyte contraction function: a receptor agonist, an ion channel blocker, and a Myosin Inhibitor. The findings suggest that the SRIS platform proficiently captures the effects of both electrode size and drug concentration on cardiomyocyte contraction properties, thereby demonstrating its precise pharmacological assessment. This facilely fabricated, cost-effective, and size-regulable cardiomyocyte contraction biosensing platform holds significant potential for applications in cardiology and pharmacology research.

Keywords

Cardiomyocyte model; Drug evaluation; Mechanical contractility; Multi-channel detection platform; Size-regulable impedance sensor (SRIS).

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-13813
    99.64%, Myosin II Inhibitor